Previous 10 | Next 10 |
Royalties increased by 18% to $111.1 million in the fourth quarter of 2021, compared to the same quarter in 2020; royalties increased by 19% to $405.7 million in full year 2021, compared to the prior year. Announced strategic investment of $45.0 million into Armata Pharmaceuti...
Armata Pharmaceuticals (NYSE:ARMP) will sell its shares and warrants to Innoviva Strategic Opportunities, a subsidiary of Innoviva (NASDAQ:INVA) - Armata's largest shareholder. The gross proceeds from the transaction are expected to be $45M, before deducting estimated offering expenses. Innov...
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development PR Newswire MARINA DEL REY, Calif. , Feb. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "C...
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! We’re beginning another busy day of trading with a look at the biggest pre-market stock movers for Wednesday! Source: ventdusud / Shutterstock.com News moving stocks this morning inclu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pharmaceutical stocks haven’t really had much since the pandemic hit. Most of the talk has been about the companies in a race for vaccines or treatments and the companies that are distributing vaccines and treatments...
Pharma/biotech is the most attractive subsector. The most overvalued one is life science tools. IXJ: an alternative to XLV. 10 stocks cheaper than their peers in December. For further details see: IXJ: Healthcare Dashboard For December
Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November
Royalties increased by 10% to $101.3 million in the third quarter of 2021, compared to the same quarter in 2020. Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) today reported financial results for the third quarter ended September 30...
Results so far in 2021 have been impressive, with both revenue and net income much higher than the same periods in either 2020 or 2019. That said, the company fired a massive buyback program in the 2nd quarter and it seems the market yawned. This makes me wonder what will happen absen...
News, Short Squeeze, Breakout and More Instantly...
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strate...